{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-067871","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.901851+00:00","generated_at":"2026-05-24T01:27:11.480772+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly","bullets":["30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.","Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).","Relacorilant well-tolerated; no new safety signals; safety comparable between groups.","Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.","Trial enrolled 381 patients globally; biomarker selection not required."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-067871","json":"https://secwatch.observer/filing/0001193125-25-067871.json","markdown":"https://secwatch.observer/filing/0001193125-25-067871.md","text":"https://secwatch.observer/filing/0001193125-25-067871.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/0001193125-25-067871-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000119312525067871/d924664d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:27:11.480772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}